Professor Peter Sandercock, MA, DM, FRCPE, FMedSci is an Academic Clinical Neurologist at the University of Edinburgh. He studied Medicine at the University of Oxford, and undertook his postgraduate clinical training in Stoke-on-Trent, Manchester, Oxford and Liverpool, followed by a visiting academic fellowship at McMaster University Canada. His initial research was on the epidemiology of stroke in Oxfordshire, and in clinical trials of stroke prevention. When he took up his post in Edinburgh he set up and ran the first International Stroke Trial (IST-1), the first ‘mega-trial’ in acute ischaemic stroke. It tested aspirin & heparin in 19.435 patients recruited within 48 hours of stroke onset from 467 hospitals in 37 countries. He is the Co-Chief Investigator of IST-3, the largest-ever trial of ‘clot-busting’ thrombolytic therapy for acute ischaemic stroke with 3035 patients. He was Co-ordinating Editor of the Cochrane Stroke Research Group (CSRG) for over 10 years, and still remains active in the group.